Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review

被引:480
作者
Austin, MA
Hutter, CM
Zimmern, RL
Humphries, SE
机构
[1] Univ Washington, Sch Publ Hlth & Community Med, Inst Publ Hlth Genet, Seattle, WA 98195 USA
[2] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Cambridge, Strangeways Res Lab, Publ Hlth Genet Unit, Cambridge, England
[4] UCL Royal Free & UCL Med Sch, Dept Med, British Heart Fdn Labs, Ctr Genet Cardiovasc Disorders, London, England
关键词
epidemiology; genetics; hypercholesterolemia; familial; LDLR; receptors; LDL;
D O I
10.1093/aje/kwh236
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The clinical phenotype of heterozygous familial hypercholesterolemia (FH) is characterized by increased plasma levels of total cholesterol and low density lipoprotein cholesterol, tendinous xanthomata, and premature symptoms of coronary heart disease. It is inherited as an autosomal dominant disorder with homozygotes having a more severe phenotype than do heterozygotes. FH can result from mutations in the low density lipoprotein receptor gene (LDLR), the apolipoprotein B-100 gene (APOB), and the recently identified proprotein convertase subtilisin/kexin type 9 gene (PCSK9). To date, over 700 variants have been identified in the LDLR gene. With the exception of a small number of founder populations where one or two mutations predominate, most geographically based surveys of FH subjects show a large number of mutations segregating in a given population. Studies of the prevalence of FH would be improved by the use of a consistent and uniformly applied clinical definition. Because FH responds well to drug treatment, early diagnosis to reduce atherosclerosis risk is beneficial. Cascade testing of FH family members is cost effective and merits further research. For screening to be successful, public health and general practitioners need to be aware of the signs and diagnosis of FH and the benefits of early treatment.
引用
收藏
页码:407 / 420
页数:14
相关论文
共 138 条
  • [91] Nauck M S, 2001, Hum Mutat, V18, P165, DOI 10.1002/humu.1171
  • [92] Detection of a novel exon 4 low-density lipoprotein receptor gene deletion in a Swiss family with severe familial hypercholesterolemia
    Neff, D
    Ruschitzka, F
    Hersberger, M
    Enseleit, F
    Hürlimann, D
    Noll, G
    Lüscher, T
    Hänseler, E
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (03) : 266 - 271
  • [93] Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105
  • [94] Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002
    Neil, HAW
    Hammond, T
    Mant, D
    Humphries, SE
    [J]. BRITISH MEDICAL JOURNAL, 2004, 328 (7438): : 500 - 501
  • [95] Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study
    Neil, HAW
    Hammond, T
    Huxley, R
    Matthews, DR
    Humphries, SE
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7254): : 148 - 148
  • [96] NISSEN H, 1995, CLIN CHEM, V41, P419
  • [97] OTT J, 1974, AM J HUM GENET, V26, P598
  • [98] PATTERSON D, 1972, LANCET, V1, P393
  • [99] PEDERSEN TR, 1994, LANCET, V344, P1383
  • [100] Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics
    Peeters, AV
    VanGaal, LF
    duPlessis, L
    Lombardi, MPR
    Havekes, LM
    Kotze, MJ
    [J]. HUMAN GENETICS, 1997, 100 (02) : 266 - 270